Abstract
Background:
Teenagers and young adults (TYAs; ages 16–24 in the United Kingdom) with cancer have specific needs and experience worse physiological and psychological outcomes compared with pediatric and adult cancer. In the United Kingdom, psychosocial screening is a mandatory part of TYA care. However, there is a lack of age-appropriate and acceptable psychosocial measures for this population. This review aimed to (1) identify the psychosocial measures utilized and available for TYA cancer and (2) describe their psychometric properties.
Methods:
We searched five databases for studies meeting the eligibility criteria. We extracted data relevant to the review and assessed study quality using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guidelines and the Hughes Quality Assessment Tool developed by the research team.
Results:
We identified 40 studies that included 105 psychosocial measures. The main constructs measured were distress, depression, and anxiety. The TYA age range varied widely. Reporting of psychosocial measures and their psychometric properties was poor, and most measures were not validated or developed for TYA cancer populations.
Discussion:
There is an urgent need for psychosocial measures that are designed for and validated in TYA cancer populations. Appropriate measures would enable clinicians to reliably identify and effectively support the psychosocial challenges faced by TYAs. The use of validated psychosocial measures enables earlier detection of difficulties, fosters patient-centered care, and is cost-effective since resources can be allocated to those most in need.
Introduction
The transition from childhood to adulthood is particularly difficult for teenagers and young adults (TYAs; ages 16–24 in the United Kingdom) due to physical, psychological, and financial challenges.1–3 This is a period when TYAs are developing a stable identity, exploring independence from their family, and making important decisions about their future.4–6 A cancer diagnosis can impact normative development during this period and cause substantial distress during and after recovery.7,8 Cancer can cause loneliness and changes to the self-concept that may affect how TYAs cope with treatment.9,10 Treatment can interfere with day-to-day life due to fatigue, nausea, and a loss of confidence that arises from changes in appearance. 1 The type and length of treatment can reduce resilience, 2 while prolonged treatment can cause feelings of helplessness2,10 and can be detrimental to relationships, education, and employment.11,12
TYAs with cancer have specific needs compared with pediatric and adult cancer and require specialist services specifically tailored to this age group.1,7,13 They experience more complex emotional and social challenges compared with other groups and require extra support in navigating finances, treatment options, and advocacy concerns.6,8 TYAs also have worse cancer survival rates compared with children and adults for several cancers, including breast cancer compared with adult populations and acute lymphoblastic leukemia compared with children. 14 This suggests that the biology of some cancers differs in TYAs compared with pediatric and adult populations. 14
The definition of TYA varies across countries, resulting in a lack of consistent research across the field.12,15,16 In the United Kingdom, the TYA age range is defined as ages 16–24, 17 but elsewhere TYAs have been defined as 15–39. 18 Past research has shown that TYAs are less likely to be referred for psychological support compared with younger children 13 and feel less involved in health care discussions. 11 More research into TYA cancer is needed to improve treatment, increase awareness of psychosocial difficulties, and ensure TYAs have a voice in their care.
In recognition of these discrepancies in care and outcomes, The National Institute for Health and Care Excellence (NICE) in the United Kingdom has made specific recommendations for TYAs with cancer. These include the use of psychosocial measures to identify those at risk of distress1,19 and access to appropriate psychological and social support.20,21 Psychosocial screening should form a standard of psychosocial care,15,22–24 but there have been challenges in implementing evidence-based screening 25 due to a lack of acceptable and appropriate psychosocial measures.26,27 All health care professionals can benefit from appropriate psychosocial measures to quickly identify TYAs at risk of emotional difficulties. Such measures should address a range of issues, including treatment-related distress, relationships, and social issues,11,15,16 while also identifying resilience and coping resources to aid adjustment to cancer.6,15,28
Past studies have used a range of terms to describe psychosocial screening, often using them interchangeably. “Screening tools” are short assessments that aim to identify people with a construct of interest such as distress. 29 “Outcome measures” refer to instruments that capture the patient's function at baseline (sometimes called screening) and following a treatment or intervention. 30 “Patient-reported outcome measures” (PROMs) are self-administered questionnaires that directly assess a patient's health status. 31 Since outcome monitoring may be used as a long-term approach to screening, 24 this review uses the term “psychosocial measure” to encompass all forms of psychosocial screening.
In the United Kingdom, psychosocial screening is a mandatory part of TYA cancer care and is important for guiding interventions. 17 However, it is unclear what validated psychosocial measures are available in this age group and clinical population. The British Psychological Society recommends that psychosocial measures used in cancer should be validated with standardized norms, 32 and that clinicians should be aware of the psychometric properties and clinical utility of measures. However, in TYA cancer, there is a lack of research into appropriate measures and their properties.19,33 Validating existing psychosocial measures could be one solution, but new measures developed specifically for this group may also be needed. 19
Review aims
To address the lack of research into age-appropriate and acceptable psychosocial measures for TYA cancer, this review aimed to (1) identify the psychosocial measures utilized and available for TYAs with cancer and (2) describe their psychometric properties.
Methods
This systematic review adhered to the PRISMA guidelines 34 and was registered with PROSPERO (07/02/22; Reg. No. CRD42022297985). 35 We used the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guidelines to extract psychometric properties and assess the quality of studies meeting COSMIN's inclusion criteria. 36
Data sources
Searches were conducted on April 6, 2022, and updated on May 12, 2023, on the following five databases: OVID MEDLINE, OVID Embase, OVID PsycINFO, EBSCO CINAHL, and Web of Science.
Search terms and strategy
Using the Patient, Intervention, Comparison, Outcome (PICO) framework 37 the main concepts identified were cancer, teenagers and young adults, and psychosocial measures. The keywords and subject headings are listed in Table 1. Each main concept was searched together using AND. No restrictions were set for publication date, peer-reviewed publications, dissertations, or poster/conference abstracts. No language restrictions were set at initial search.
Search Terms
After removing duplicates, identified articles were screened by the author (K.H.) based on title and abstract. A second reviewer (L.B.) independently screened 20% of the articles, also based on title and abstract, to check that the criteria were being followed objectively. All articles screened by L.B. were randomly selected. Initial agreement about eligible articles between the two reviewers was 99% based on titles and abstracts and 100% following discussions. Articles were excluded based on the criteria below. Full texts were screened by K.H. using the criteria below and 20% of these texts were screened by L.B. Initial agreement was 90% for the full texts and 100% following discussions.
Inclusion/exclusion criteria
Studies were included or excluded if they met the criteria shown in Table 2.
Inclusion and Exclusion Criteria
TYA, teenagers and young adult.
COSMIN guidelines include the following eligibility criteria for systematic reviews of psychosocial measures
36
:
Measures should measure the construct of interest, in this case, psychosocial difficulties such as distress, anxiety, or depression The study sample should represent the population of interest, in this case TYA cancer The study should concern psychosocial measures The study's aim should be to evaluate psychometric properties or to develop a measure
However, as our primary aim was to identify which psychosocial measures are used in TYA cancer, we purposefully included studies only using psychosocial measures and not developing or evaluating them. Therefore, it was not possible to comply with COSMIN's guidelines for all studies.
Data extraction
We extracted data based on COSMIN guidelines, past reviews, and discussions with clinicians. Data were extracted from all the included articles by K.H. and 20% of data extraction was repeated by L.B. Agreement was reached on 100% of the data extracted. See Supplementary Data SA for full details of what the data extraction table included.
Some studies in this review included multiple measures, meaning there were more measures than studies.
Psychometric properties for articles suitable for COSMIN evaluation
COSMIN can be used as a modular tool, and so, we only included sections that were relevant for our review. 36 For articles meeting the COSMIN eligibility criteria, we extracted structural validity, internal consistency, cross-cultural validity/measurement invariance, and reliability (see Supplementary Table S1 for definitions of each property). We also collected information on criterion validity, however, there were no identified gold standard psychosocial measures in this population (required for COSMIN assessment of criterion validity), and therefore, this information is presented in Supplementary Table S2 but does not form part of the main quality assessment.
These properties were rated using COSMIN criteria for good measurement properties 36 as sufficient (+), insufficient (−), or indeterminate (?). COSMIN recommends pooling findings together to identify the most suitable measure. However, this was not possible due to the small number of measures identified and the wide range of constructs covered.
Psychometric properties for measures that did not meet COSMIN eligibility criteria
For measures not meeting COSMIN criteria, we searched the full texts for the following psychometric properties: internal consistency, test–retest reliability, construct validity, sensitivity, and specificity. To ease comparison, we grouped these measures as follows: (1) noncancer populations; (2) cancer populations but not specific to TYA; and (3) TYA cancer populations.
We used narrative synthesis to summarize these psychosocial measures and their psychometric properties. The approach involved summarizing the findings from the different studies based on the use of words, text, and reported psychometric properties.
Quality assessment
All articles retained after screening were assessed by K.H. using either the COSMIN Risk of Bias checklist 38 or a quality assessment tool developed by the research team (Hughes Quality Assessment Tool, described below). Fifty percent of these articles were also assessed by L.B. and final agreement was reached on 100% of the articles.
COSMIN Risk of Bias checklist 38
The COSMIN Risk of Bias checklist was used to assess the quality of studies meeting the COSMIN eligibility criteria. This checklist was used as a modular tool and further information about the tool can be found in Supplementary Data SA.
The methodological quality of each section was rated as very good, adequate, doubtful, or inadequate based on COMSIN criteria. Overall ratings of each section were given the lowest rating of any criteria within that domain, that is, “worst score counts.” 36 Since the aim of this review was to identify the psychosocial measures utilized and available in TYA cancer, all studies were included, regardless of quality.
Hughes Quality Assessment Tool
For articles that could not be quality assessed using the COSMIN Risk of Bias checklist, we used an alternative quality assessment tool created by the research team. This tool was guided by criteria created to review health status and quality-of-life tools 39 and assessed (1) the conceptual and measurement model; (2) reliability and validity; (3) interpretability; (4) mode of administration; and (5) cultural or language adaptations (see Supplementary Data SA for details).
Results
Aim 1: Identify the psychosocial measures utilized and available for TYAs with cancer
Overview of studies
From the five databases, we identified 1020 articles after the removal of duplicates (Fig. 1). One thousand twenty articles were excluded based on title and abstract screening, mostly due to the articles not being about TYAs or being about an illness other than cancer. Of the remaining 106 articles, full texts were retrieved for 60 articles. We were unable to retrieve full texts for 46/106 articles, despite contacting all the corresponding authors who had shared their email to request full texts. Many of the full texts could not be retrieved as they were conference or poster abstracts (n = 40). Of the 60 articles retrieved, 20/60 were excluded as they did not meet the eligibility criteria for this review.

PRISMA flowchart of search results.
Excluded articles were those addressing measures for TYA cancer survivors (n = 3); not mentioning a measure (n = 8); not defining a TYA age range (n = 4); study protocol (n = 1); not providing any details about the measure (n = 2); combined TYA cancer with chronic illness (n = 1); and not written in English (n = 1). 40 studies were therefore included in this review.
Study and measure characteristics
The 40 studies were carried out in 12 countries. These countries were predominantly the United States (n = 10 studies), Canada (n = 7), China (n = 4), Germany (n = 3), Australia (n = 4), the United Kingdom (n = 2), Japan (n = 2), India (n = 2), and Singapore (n = 2). One study was carried out across four countries (Australia, Canada, the United Kingdom, and the United States). The remaining studies were carried out in a single country (see Supplementary Table S3).
A total of 33/40 studies were carried out in a research setting and 7/40 in a clinical setting. TYA ages ranged from 11 to 45, and the most commonly reported age ranges were 15–39 (n = 15) and 18–39 (n = 11). The UK definition of TYAs aged 16–24 was used in only one study. Most studies covered a wide range of cancer diagnoses, but two focused on breast cancer only and one on germ cell tumors only.
We identified 105 measures across the 40 studies, since some studies included multiple measures (see Table 3). We identified measures in eight languages; predominantly English (n = 25 studies), Chinese (n = 4), and German (n = 3). A total of 53/105 (50%) measures were screening tools, 25/105 (24%) were outcomes, 16/105 (15%) were validation tools, 8/105 (8%) were predictors, 2/105 (2%) were outcomes and predictors, and 1/105 (1%) was a covariate. A total of 41/105 (39%) measures were self-report with no mode of administration mentioned, 22/105 (21%) were paper self-report, 18/105 (17%) were paper or electronic self-report, 17/105 (16%) were electronic self-report, 3/105 (3%) were face-to-face interviews, 2/105 (2%) were not stated, and 2/105 (2%) were not applicable as the articles focused on a discussion around the development of the measure.
Overview of Studies and Measures
The main constructs measured were distress (31/105 measures, 30%), depression (19/105, 18%), anxiety (16/105, 15%), quality of life (9/105, 9%), social support (6/105, 6%), psychosocial health/functioning (5/105, 5%), symptom burden (3/105, 3%), and medical coping (3/105, 3%). Despite distress being the most commonly measured construct, it was clearly defined in only two articles40,41 as an unpleasant emotional experience, which can be psychological, social, or emotional, and can range from feelings of sadness to clinical symptoms of psychological difficulties.
The most commonly reported measures were as follows: Distress Thermometer with associated problem/concern checklist (12/105 measures, 11%); Hospital Anxiety and Depression Scale (9/105, 9%); Patient Health Questionnaire in various forms, for example, PHQ-9, PHQ-8, PHQ-2 (6/105, 6%); Distress Thermometer only (5/105, 5%); Kessler Psychological Distress Scale-10 and 6 (4/105, 4%); Generalized Anxiety Disorder Scale-7 (4/105, 4%); Canadian Problem Checklist (3/105, 3%); Pediatric Quality of Life Inventory (3/105, 3%); Cancer Distress Scales for Adolescents and Young Adults (3/105, 3%); and the PsychoSocial Screen for CANcer-Revised (3/105, 3%).
Quality assessments
A total of 74/105 measures were assessed using the Hughes Quality Assessment Tool (see Supplementary Table S4) and 15/105 were assessed using the COSMIN Risk of Bias checklist 38 (see Supplementary Table S5). The remaining 16/105 measures were validation tools and were therefore not quality assessed.
Hughes Quality Assessment Tool
Conceptual and measurement model
The concept being measured was fully defined in 72/74 (97%) measures and partially defined in 2/74 (3%). The population that the measure was validated in was adequately described in 29/74 (39%) measures, partially described in 21/74 (28%), and not described in 24/74 (32%). The measure was validated in a TYA cancer population for 13/74 (18%) measures.
Reliability
Reliability was reported for 29/74 (39%) measures. Internal consistency was reported for 18/74 (24%) measures with 14/74 (19%) reporting a statistic. Test–retest reliability was reported for 2/74 (3%) measures with none reporting a statistic. Where no statistic was reported, a statement such as “good test–retest reliability” was stated.
Validity
Validity was reported for 39/74 (53%) measures. A total of 3/74 (4%) reported on construct validity specifically, but gave no statistic, and 2/74 (3%) reported on convergent validity, but again gave no statistic.
Interpretability
Very clear explanations of how to interpret scores were given for 35/74 (47%) measures, 29/74 (39%) were partially clear, 6/74 (8%) were not clear, and 4/74 (5%) were not stated. Cutoffs were reported for 33/74 (45%) measures.
Method of administration
The method of administration was reported for 61/74 (82%) measures, which was predominantly self-report (39 measures), paper self-report (16), and online self-report (11).
Cultural and language adaptations
A total of 23/74 (31%) measures were translated into another language and the psychometric properties were evaluated for 10 of these measures.
COSMIN Risk of Bias checklist
A total of 15/105 measures were rated using this checklist.
PROM development
The development of 6/15 (40%) measures was reported; 4 were rated as inadequate and 2 were doubtful.
Content validity
Patients were asked about the relevance, comprehensiveness, and comprehensibility for 5/15 (33%) measures, with the majority of methodologies being rated as doubtful, except McGrady et al., 42 which had comprehensiveness and comprehensibility rated as adequate, and Patterson et al., 43 which had all areas rated as adequate. Professionals were asked about relevance for 8/15 (53%) measures and comprehensiveness for 3/15 (20%). All were rated as doubtful except for Patterson et al., 43 which was rated as adequate.
Structural validity
Structural validity was reported for 4/15 (27%) measures; 3 were rated as very good and 1 as inadequate.
Internal consistency
Internal consistency was reported for 7/15 (47%) measures and all were rated as very good.
Cross-cultural validity
Cross-cultural validity was reported for 5/15 (33%) measures, with 4 rated as inadequate and 1 as doubtful.
Reliability
Reliability was reported for 8/15 (53%) measures, with 4 rated as inadequate and 4 as doubtful.
Measurement error
Measurement error was not reported for any measures.
Construct validity
Convergent validity was reported for 11/15 (73%) measures; 6 were rated as adequate, 4 as doubtful, and 1 as inadequate. Discriminative or known group validity was reported for 7/15 (47%) measures, with 2 rated as very good and 5 as doubtful.
Responsiveness
A total of 11/15 (73%) measures were compared with other instruments. Six were rated as adequate, 4 as doubtful, and 1 as inadequate. A total of 7/15 (47%) measures were compared between subgroups; 5 were rated as doubtful and 2 as very good. A total of 5/15 (33%) measures were compared before and after an intervention and all were rated as doubtful.
Aim 2: Describe the psychometric properties of these measures
Of the identified measures, only 45/105 reported psychometric properties and are therefore included in this section. A total of 15/105 were rated using COSMIN guidelines to describe their psychometric properties. A total of 30/105 measures reported psychometric properties but were not rated using COSMIN guidelines; 8 of these measures were validated in noncancer populations, 7 were validated in cancer populations, and 15 were validated in TYA cancer populations.
Measures rated using COSMIN guidelines (15/105)
The psychometric properties of these measures were rated against the criteria for good measurement properties as stated in COSMIN guidelines and full details of the reported properties can be found in Supplementary Table S6.
Structural validity
Structural validity was reported for 4/15 (27%) measures. All measures were rated as insufficient as they did not report adequate goodness-of-fit statistics except for one measure, which was rated as sufficient.
Internal consistency
Internal consistency was reported for 7/15 (47%) measures, with 6 rated as sufficient (Cronbach's alpha or omega ≥0.70) and 1 as insufficient (Cronbach's alpha or omega <0.70).
Cross-cultural validity/measurement invariance
Cross-cultural validity/measurement invariance was reported for 5/15 (33%) measures, with four rated as indeterminate and one as adequate. Four were indeterminate as they did not carry out multiple group factor analysis or differential item functioning. One was only adequate as there was no important differential item functioning for group factors.
Reliability
Reliability was reported for 9/15 (60%) measures, with six rated as sufficient and three as insufficient. Measures were rated as sufficient if they had an intraclass correlation coefficient (ICC) of greater than or equal to 0.70.
Measures that were not rated using COSMIN guidelines (30/105)
Psychometric properties were extracted for the remaining measures, and full details are reported in Supplementary Tables S7–S9.
Psychometric properties were reported for eight measures that were validated in noncancer populations
Internal consistency (Cronbach's alpha) was reported for 7/8 (88%) measures and ranged from 0.67 to 0.94. Test–retest reliability (ICC) and construct validity (mean difference [standard error; SE]) were reported for 1/8 (13%) measures and sensitivity/specificity was reported for 1/8 (13%) measures.
Psychometric properties were reported for seven measures that were validated in cancer populations, but were not specific TYA cancer populations
Internal consistency (Cronbach's alpha) was reported for 4/7 (57%) measures and ranged from 0.82 to 0.9. Test–retest reliability (ICC) was reported for 2/7 (29%) measures and ranged from 0.73 to 0.84. Construct validity (mean difference [SE]) was reported for 2/7 (29%) measures and sensitivity/specificity was reported for 2/7 (29%) measures.
Psychometric properties were reported for 15 measures that were validated in TYA cancer populations
Internal consistency (Cronbach's alpha) was reported for 11/15 (73%) measures and ranged from 0.56 to 0.96, while sensitivity/specificity was reported for 5/15 (33%) measures.
Discussion
This systematic review found 105 psychosocial measures used in TYA cancer populations in 40 studies carried out across 12 countries. Most measures were used in a research setting, covered a wide range of cancer diagnoses, were self-report, and were predominantly written in English. The reported age ranges varied widely, with the most commonly reported ages being 15–39 and 18–39. Only one study met the UK definition of TYA (ages 16–24). The most commonly measured constructs were distress, depression, and anxiety, and the most commonly reported measure was the Distress Thermometer with associated problem/concern checklist. Very few measures were developed (6/105, 6%) and/or validated (28/105, 27%) in a TYA cancer population. Studies were generally of poor quality due to the lack of validation in TYA cancer, poor testing or reporting of psychometric properties, and where psychometric properties were reported, the methods used were often doubtful or insufficient.
Previous research has shown that TYAs with cancer are at increased risk of distress, depression, and anxiety, which can have an impact on pain, length of hospital admission, and treatment adherence.44,45 It was therefore predictable that the most commonly measured constructs in this review were distress, depression, and anxiety and that the Distress Thermometer with associated problem/concern checklist was the most frequently reported measure. However, distress was only defined in two studies,40,41 meaning the construct being measured was unclear and there were possible overlaps with depression and anxiety. 45 The Distress Thermometer is frequently used in adult cancer although there have been criticisms that this single-item measure could overestimate levels of distress. 46 Using the Distress Thermometer with an associated problem/concern checklist may address this criticism.
No measures were developed for a specific cancer diagnosis or treatment type, and only three studies focused on a single type of cancer. Given the large variation in the physiological and psychological impacts of different diagnoses and treatments, 2 it would be beneficial to explore whether the measures' psychometric properties are stable across multiple diagnoses and treatments. Future research should focus on validating psychosocial measures for specific diagnoses and treatment types to address this gap in the literature.
Wide variations in the TYA age range across studies and countries highlight the lack of consistency in classifying this group. From a physiological and developmental perspective, those in their late adolescence and early twenties have very different needs from those in their 30s47,48; measures developed and validated in TYAs aged 18–39 might be inappropriate for those aged 16–24. Consistency across TYA cancer research is required to understand the needs of this group, create appropriate measures, and develop suitable interventions. It has also been suggested that presenting validation data for subgroups of TYAs (e.g., those aged 16–18 and 18–24) could help manage the challenges around defining this age group.19,47
Most studies in this review were conducted in a research setting (33/40) rather than a clinical setting (7/40). Therefore, the reported psychosocial measures provide little insight into which measures are used in clinical setting. This suggests that increased reporting of screening tools in clinical settings is needed. For example, future research should use alternative methods (e.g., directly surveying clinicians) to better understand which measures are used in clinical practice and their reliability and validity for the TYA population.
The reporting of psychometric properties was almost universally poor. Previous research into adult and pediatric cancer has also highlighted poor reporting of psychometric properties,49,50 suggesting that something has been overlooked more broadly across the cancer field. Very few measures were developed and validated in TYA cancer populations. For clinicians to be confident that measures are reliably capturing the constructs they purport to, it is crucial for studies to report psychometric properties to identify measures with acceptable validity, reliability, and sensitivity.19,46 It is also important for cross-cultural validity to be explored, given that TYAs with cancer are from diverse backgrounds, and culture can influence coping strategies and treatment adherence. 51
Although our review was restricted to publications written in English, and therefore found most measures were written in English, it is vital for psychosocial measures to be translated and validated in a range of languages to ensure they are culturally sensitive and inclusive for all.
Our findings suggest several recommendations for future studies in TYA cancer. First, a consistent age range should be agreed upon, and psychosocial measures should be developed and validated for this age group. Second, psychosocial measures should be specifically tailored for this age group to include relevant issues such as education, work, and finances. Third, given the variability across cancers, it will be important to develop and validate psychosocial measures for specific diagnoses and treatment types. However, when screening for specific conditions such as anxiety or depression, it will still be necessary for psychosocial measures to meet certain standards, such as those based on ICD-1152 and DSM-V 53 criteria that are consistent across all ages and cancer diagnoses and treatments.
Finally, validation studies must consistently report psychometric properties and clinical thresholds. This will enable clinicians to use appropriate, validated scales to identify TYAs requiring further assessment and to allocate psychosocial interventions to those most in need.
Strengths and limitations
This was the first study to comprehensively review the psychosocial measures utilized and available in TYA cancer. We assessed the quality and psychometric properties of the included studies and measures. While most studies were rated as poor quality, this review provides clear guidance for future research to address this significant gap in TYA cancer care.
In terms of limitations, we restricted our review to published studies written in English, excluding measures reported in gray literature or published in another language. Second, the gold standard for assessing the methodology and reporting psychometric properties of measures would be to follow COSMIN guidelines. 36 However, given that the main aim of this review was to identify the psychosocial measures utilized and available TYA cancer, these guidelines could not be followed for all studies as they did not solely focus on the development or psychometric properties of measures in this population. The research team therefore developed a quality assessment tool that was appropriate for the studies included in this review that did not meet COSMIN's inclusion criteria, but this tool has not been peer reviewed.
It was thus challenging to draw common themes around methodological quality. In addition, a large proportion of the measures included were not validated in TYA cancer populations.
Conclusion
The use of psychosocial measures throughout cancer diagnosis and treatment can lead to early detection of mental health difficulties, which allows for proactive rather than reactive interventions.46,54 Regular psychosocial screening at key intervals from cancer diagnosis to follow-up/bereavement could identify those in need of support, distribute resources effectively, and tailor interventions appropriately.20,48 This systematic review identified a number of psychosocial measures available for TYAs with cancer, which predominantly measured distress, depression, and anxiety. However, there was wide variation in the TYA age range and types of cancer, both within and between studies. Most measures were not validated in a TYA cancer population and reporting of psychometric properties was poor. This review highlights a crucial need for measures to be validated specifically in TYA cancer populations if we are to reliably screen for, and support effectively, distress in young people with cancer.
Footnotes
Acknowledgments
We would like to thank all the patients and their families who have contributed to this body of research, and all the authors who took time to respond to queries about their data. We would also like to thank the reviewers of this article who provided helpful and insightful comments that have contributed to this review.
Authors' Contributions
K.H. was involved in the review's conceptualization, database searches, screening, data extraction, quality assessments, and write-up. L.B. was involved in screening, data extraction, and quality assessments. E.C., S.H., and C.J. provided supervision and guidance for the review's conceptualization, analysis, and write-up.
Author Disclosure Statement
An article written by C.J. was included in this review, however, only K.H. and L.B. were involved in the assessment of this article.
Disclaimer
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.
Funding Information
This article represents independent research, in part, funded by the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The grant code is NIHR203318.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
